Sort   by:  
 Page size 
UnknownPositive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Not available
S-EPMC9292745 | biostudies-literature
UnknownSafety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions
Not available
S-EPMC12030940 | biostudies-literature
UnknownComparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis.
Not available
S-EPMC5685605 | biostudies-literature
UnknownHepatitis B and HIV coinfection in Northern Uganda: Is a decline in HBV prevalence on the horizon?
Not available
S-EPMC7673526 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Not available
S-EPMC7576974 | biostudies-literature
UnknownAnalysis and clinical determinants of post-COVID-19 syndrome in the Lombardy region: evidence from a longitudinal cohort study.
Not available
S-EPMC10860093 | biostudies-literature
UnknownNatural history of human Monkeypox in individuals attending a sexual health clinic in Milan, Italy.
Not available
S-EPMC9628937 | biostudies-literature
UnknownSwitch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
Not available
S-EPMC5065232 | biostudies-literature
UnknownNeurobrucellosis Presenting with Motor Damage or Hearing Loss, and Use of Steroids are Associated with a Higher Risk of Sequelae or Relapse: A Systematic Review of Individual Participant Data.
Not available
S-EPMC11470871 | biostudies-literature
Unknown
Not available
S-EPMC11868795 | biostudies-literature
Sort   by:  
 Page size